A Phase I Study of Oral Topotecan in Subjects With Cancer and Impaired Renal Function
1. Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form.
2. Age 18 years or older.
3. A performance status score of 0, 1, or 2 on the Eastern Cooperative Oncology Group
4. Histologically- or cytologically-confirmed advanced solid tumors.
5. Failed conventional therapy for their tumor type; or subjects who have a tumor type
for which no standard effective therapy exists; or subjects for whom single-agent
topotecan therapy is suitable.
6. Completion of a 24-hour urine collection within 14 days prior to the first dose to
calculate the creatinine clearance value and determine the renal impairment category
(refer to Appendix 8).
7. Using Cockcroft-Gault formula (refer to Appendix 6), documentation of stable renal
function should be performed within 14 days of the first scheduled dose of study
medication using at least 2 serum creatinine values separated by a minimum of 7 days.
Stable renal function is defined as:
1. ≤25% change for CrCl <40 mL/min or
2. ≤10 mL/min change for CrCl ≥40 mL/min NOTE: Documentation of stable renal
function will NOT be required if the 24-hour urine collection to determine the
renal impairment category is completed within 7 days prior to the first dose.
- Currently undergoing dialysis.
- Pregnant or lactating.
- Women of childbearing potential who refuse to either abstain from sexual intercourse
or practice adequate contraception
- Male subjects with female partners of childbearing potential who have not had a prior
vasectomy or if both the male subject and the female partner refuse to use adequate
contraception beginning 14 days before exposure to study drug, continuing throughout
the clinical trial, and for a period of 3 months after the last dose of study drug.
- Uncontrolled emesis, regardless of etiology.
- Bilirubin > 1.5 X ULN.
- SGOT/AST, SGPT/ALT and alkaline phosphatase >2 times the upper limit of normal (ULN)
if no evidence of potentially associated metastases (e.g., liver or bone) by computed
tomography (CT) or magnetic resonance imaging (MRI). If potentially associated
metastases (e.g., liver or bone) are present, subjects with <5 times ULN are eligible
to participate, following discussion with and approval from a GSK Medical Monitor.
Hematological values outside of acceptable ranges. Active infection. Prior anti-cancer
therapy, including, but not limited to, chemotherapy (except nitrosurea or mitomycin C),
radiotherapy, biologic therapy, investigational therapy or major surgery within 21 days of
the first scheduled dose of study drug. Prior nitrosurea of mitomycin C chemotherapy
within 6 weeks of first scheduled dose of study drug. Failure to recover to Grade 1 or
better from any toxicity (except alopecia) related to prior anti-cancer therapy by Day 1,
Course 1 unless agreed to by a GSK Medical Monitor and the Investigator. Clinical evidence
of a gastrointestinal (GI) condition (i.e., removal of a portion of the stomach, recent GI
obstruction or GI neuropathy) or taking drugs that would alter GI absorption or motility.
Currently taking or will require treatment with cyclosporin A. Concurrent severe medical
problems unrelated to the malignancy, which would significantly limit full compliance with
the study or expose the subject to extreme risk (including major surgery within 21 days or
placement of biliary stents or nephrostomy tubes within 7 days). History of allergic
reactions to topotecan or compounds chemically related to topotecan (e.g., irinotecan).